Drugs / GSK4023393A
last change Feb 2024 re-read 2 minutes ago

GSK4023393A

Developed for
meningococcal infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04886154 Jun 2021 → Feb 2024 meningococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK4023393A “The purpose of this study was to assess the safety, effectiveness, and immune response of the meningococcal combined ABCWY vaccine (GSK4023393A) intended to protect against...” NCT04886154